“Eli Lilly’s First Quarter Performance: Exceeding Expectations and Projecting Growth”
Eli Lilly (NYSE: LLY) announced first-quarter earnings per share (EPS) of $2.58, surpassing the analyst consensus by $0.10, which was estimated at $2.48. Quarterly revenue stood at $8.77 billion, slightly below the consensus estimate of $8.94 billion.
Eli Lilly
For the fiscal year 2024, Eli Lilly forecasts EPS in the range of $13.50 to $14.00, compared to the analyst consensus of $12.50.
Revenue for fiscal year 2024 is projected to be between $42.40 billion and $43.60 billion, surpassing the analyst consensus of $41.44 billion.
Eli Lilly’s stock closed at $737.20, marking an increase of 11.62% over the past three months and a significant rise of 81.66% over the past year.
In the last 90 days, Eli Lilly witnessed three positive EPS revisions and five negative EPS revisions. For more information on Eli Lilly’s stock price reactions to earnings, refer to their past performance here.
According to InvestingPro, Eli Lilly’s Financial Health score indicates “good performance.”
For further details on Eli Lilly’s recent earnings performance and financials, please visit here.
Stay informed about upcoming earnings reports by accessing Investing.com’s earnings calendar.
